- Braxia Scientific (BRAX) has announced a private placement with institutional investors for gross proceeds of approximately $3 million
- The company will issue 30,000,000 common shares and warrants at a price of $0.10
- Net proceeds will be used for the expansion of clinics, certain strategic investments and general working capital purposes
- No securities were offered or sold to Canadian residents in connection with the private placement
- Braxia is a medical research company with clinics that provide innovative ketamine treatments
- Braxia Scientific Corp. (BRAX) is down 12.5 per cent on the day, trading at C$0.07 per share at 1:45 pm EST
Braxia Scientific (BRAX) has announced a private placement with institutional investors for gross proceeds of approximately $3 million.
The company will issue 30,000,000 common shares and warrants at a price of $0.10.
Each warrant will entitle the holder to purchase one share at a price of $0.125 for a period of five years following the issuance date.
H.C. Wainwright & Co. is acting as the exclusive agent for the offering
Net proceeds will be used for the expansion of clinics, certain strategic investments and general working capital purposes.
No securities were offered or sold to Canadian residents in connection with the private placement. The offering is expected to close on or about January 10, 2022, subject to satisfaction of customary closing conditions.
Braxia is a medical research company with clinics that provide innovative ketamine treatments for persons with depression and related disorders.
Braxia Scientific Corp. (BRAX) is down 12.5 per cent on the day, trading at C$0.07 per share at 1:45 pm EST.
